MN-KINDEVA-DRUG-DELIVERY
At the recent Respiratory Drug Delivery (RDD) Conference, John Patton, Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, was announced as the winner of the Charles G. Thiel Award. This prestigious award is given once every two years at RDD Conferences to one scientist who has been voted by his or her peers to have pioneered significant developments in one or more aspects of the science and technology surrounding respiratory drug delivery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508931671/en/
Biotechnology scientist and entrepreneur and Kindeva Drug Delivery’s Head of the Scientific Advisory Board, John Patton (second from the left), was named the winner of the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery at this year’s Respiratory Drug Delivery (RDD) Conference. Also pictured (from left to right): Michael Hindle, Ph.D., Professor, School of Pharmacy at Virginia Commonwealth University, Stephen Stein, Scientific Director of Inhalation Product Development at Kindeva, and Milton Boyer, CEO at Kindeva. (Photo: Business Wire)
Patton has been one of the most influential scientists in the field of respiratory drug delivery and is a champion in the field of pulmonary delivery of large molecules and biologics. He has published more than 100 publications, has more than 40 patents, and has founded or co-founded six drug delivery companies, including iPharma Labs, a company that Kindeva acquired in 2022.
“John’s research and development expertise, coupled with the myriad publications he authored, have helped pave the way for respiratory delivery to be utilized by researchers and companies for the treatment of other diseases,” said Kindeva’s Global Chief Commercial Officer, David Stevens. “John’s passion and conviction with respect to the applications of drug delivery to and through the lungs, and in particular his pioneering work progressing pulmonary delivery of biologics, has been nothing short of inspiring. John has made and continues to make a tremendous contribution to both Kindeva and the wider industry. On behalf of all his colleagues at Kindeva, we congratulate John. It is a privilege to work alongside him and benefit from his technical vision and boundless enthusiasm for inhaled medicine.”
Kindeva’s application in inhaled biologics spans complex therapeutic treatments from local to deep lung (systemic) delivery — including lung fibrosis, asthma/COPD, cardiovascular, and infectious diseases — and encompasses a wealth of expertise in developing solutions that address insulin needs, cold chain requirements, and more.
Read more about this award as well as Kindeva’s advancements in biologic drug development.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508931671/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Commencement of Commercial Operations at Calcasieu Pass17.2.2025 22:07:00 CET | Press release
Today, Venture Global announced that it has notified its long-term customers that its Calcasieu Pass facility will commence commercial operations on April 15, 2025. The facility will achieve its commercial operation date, or COD, in under 68 months from its August 2019 final investment decision, despite substantial impacts including two hurricanes, the COVID-19 pandemic, and major unforeseen manufacturing issues, such as with the Heat Recovery Steam Generators (HRSGs) forming part of the facility’s power island. Venture Global wishes to express its gratitude to its construction and completion teams who tirelessly worked to safely complete our facilities, to our vendor teams who provided invaluable support for the necessary repairs, and to our government regulators, including the Federal Energy Regulatory Commission, for their oversight and cooperation. These efforts now allow us to supply our long-term customers with the full 20-year contract term of the lowest-cost, clean LNG as promi
Frontgrade Qualifies Industry’s First Class L GaN DC-DC Converter and EMI Filter17.2.2025 17:07:00 CET | Press release
Frontgrade Technologies, a leading provider of mission critical electronics for aerospace and defense, has become the first company to successfully qualify to Class L standards its Gallium Nitride (GaN)-based DC-DC converter and complementary electromagnetic interference (EMI) filter. Under the Defense Logistics Agency’s MIL-PRF-38534 specification, Class L qualification verifies these devices’ ability to meet the most stringent performance requirements of space missions from Low Earth Orbit (LEO) through Geostationary Earth Orbit (GEO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217986495/en/ Frontgrade Technologies has become the first company to successfully qualify to Class L standards its GaN-based DC-DC converter and complementary EMI filter. (Photo: Business Wire) Frontgrade’s new isolated, single-stage converters leverage advanced GaN FET technology to provide spacecraft designers with the industry’s most effi
Ruler of Ras Al Khaimah, UAE, Says ‘Science is the Bedrock Upon Which We Build a Sustainable Future’ During Opening Address at 16th International Workshop on Advanced Materials17.2.2025 16:05:00 CET | Press release
HH Sheikh Saud bin Saqr Al Qasimi:‘Ras Al Khaimah is committed to nurturing scientific advancement and contributing to the global conversation on advanced materials’ His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, delivered an opening keynote address on the first day of the three-day International Workshop on Advanced Materials (IWAM), where he talked of science holding the key to building a more sustainable world and of how Ras Al Khaimah is committed to scientific advancement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217844634/en/ His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, delivering the opening keynote address at the International Workshop on Advanced Materials today (Photo: AETOSWire) HH Sheikh Saud said: “Through the annual hosting of IWAM, Ras Al Khaimah is reaffirming its commitment to nurturing scie
Bentley Systems Issues Call for Nominations for the 2025 Going Digital Awards17.2.2025 15:01:00 CET | Press release
Winners to be Announced at the 2025 Year in Infrastructure Conference, Taking Place in Amsterdam on October 14-15 Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced nominations are now open for the 2025 Going Digital Awards. This renowned global program recognizes the very best digital advancements in infrastructure delivery and performance. Independent jurors—consisting of thought leaders and experts in their field—select the winners from among the world’s most extraordinary infrastructure projects. The deadline for nominations is March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217405555/en/ Winners of the 2024 Going Digital Awards celebrate their accomplishments. Nominations are now open for the 2025 awards. Image courtesy of Bentley Systems. Celebrating over 20 years, the awards program has recognized more than 5,250 of the world's most outstandi
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)17.2.2025 14:46:00 CET | Press release
Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. (“PharmaEssentia”) and AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in AOP Health’s favor. At the heart of the case were reciprocal claims for damages arising from a dispute regarding a licensing agreement between the parties. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217280380/en/ Portrait: Dr. Rudolf Widmann | Member of the Board of Directors & Founder | AOP Health | Photocredit: AOP Health | Ospelt Photography The product in dispute The conflict centers around ropeginterferon alfa-2b, a substance launched in 2019 and that AOP Health has developed into an innovative treatment (BESREMi®) for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom